Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-PSMA-VG01 in PSMA-Positive mCRPC
NCT07660211Phase 1Recruiting
- Sponsor
- VitsGen Therapeutics
- Start
- Jun 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 177Lu-PSMA-VG01 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by VitsGen Therapeutics. Primary endpoints: Radiation dosimetry up to 36 weeks, Dose-Limiting Toxicities up to 6 weeks and 6 more. Started Jun 2026; status: recruiting.
02
Drugs
177Lu-PSMA-VG01
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07660211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07660211.